Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to Hold at Leerink Partnrs

Leerink Partnrs lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a hold rating in a research note issued to investors on Tuesday morning, Zacks.com reports.

A number of other analysts have also issued reports on REGN. Canaccord Genuity Group restated a buy rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating on the stock in a research note on Thursday, July 11th. JPMorgan Chase & Co. increased their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an overweight rating in a research report on Friday, August 2nd. Royal Bank of Canada lowered their price objective on Regeneron Pharmaceuticals from $1,282.00 to $1,252.00 and set an outperform rating for the company in a report on Tuesday. Finally, TD Cowen upped their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a buy rating in a research note on Tuesday, July 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $1,118.62.

Regeneron Pharmaceuticals Price Performance

REGN opened at $1,042.69 on Tuesday. Regeneron Pharmaceuticals has a twelve month low of $769.19 and a twelve month high of $1,211.20. The firm has a market cap of $114.89 billion, a price-to-earnings ratio of 31.20, a PEG ratio of 3.72 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The company has a fifty day simple moving average of $1,129.33 and a 200 day simple moving average of $1,034.03.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period last year, the firm earned $8.79 earnings per share. The company’s revenue was up 12.3% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The disclosure for this sale can be found here. Insiders sold 9,270 shares of company stock valued at $10,695,833 over the last 90 days. 7.48% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Greater Midwest Financial Group LLC grew its position in Regeneron Pharmaceuticals by 8.8% in the second quarter. Greater Midwest Financial Group LLC now owns 2,502 shares of the biopharmaceutical company’s stock worth $2,894,000 after buying an additional 203 shares during the last quarter. Centaurus Financial Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $118,000. Prio Wealth Limited Partnership acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $210,000. Sanctuary Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at $47,611,000. Finally, Kestra Investment Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $437,000. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.